Overdiagnosis in cancer
Paper cited by one bottleneck page and 21 idea pages, indexed on Europe PMC as PubMed record 20413742 and published in JNCI: Journal of the National Cancer Institute; the citing pages link this DOI, which is how the record was matched.
Overview
This article summarizes the phenomenon of cancer overdiagnosis-the diagnosis of a "cancer" that would otherwise not go on to cause symptoms or death. We describe the two prerequisites for cancer overdiagnosis to occur: the existence of a silent disease reservoir and activities leading to its detection (particularly cancer screening). We estimated the magnitude of overdiagnosis from randomized trials: about 25% of mammographically detected breast cancers, 50% of chest x-ray and/or sputum-detected lung cancers, and 60% of prostate-specific antigen-detected prostate cancers. We also review data from observational studies and population-based cancer statistics suggesting overdiagnosis in computed tomography-detected lung cancer, neuroblastoma, thyroid cancer, melanoma, and kidney cancer. To address the problem, patients must be adequately informed of the nature and the magnitude of the trade-off involved with early cancer detection. Equally important, researchers need to work to develop better estimates of the magnitude of overdiagnosis and develop clinical strategies to help minimize it.
Indexed on Europe PMC as PubMed record 20413742 (DOI 10.1093/jnci/djq099). Matched by DOI alone: one bottleneck page and 21 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 21 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- Key paperPATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms
Shares A mandatory decision aid before any multi-cancer blood test, Overdiagnosis and false alarms.
- CancerThyroid cancer
Shares Active surveillance as the default for tiny papillary thyroid cancers, Modern autopsy studies to measure how much silent cancer people carry, Stop biopsying small thyroid nodules and never screen the thyroid, An international body to rename indolent lesions so 'cancer' means something.
- BottleneckOlder and multimorbid patients are excluded and undertreated
Shares Stop screening by life expectancy, not birthday, with a tool in the record, Hormone tablets instead of surgery for small breast cancers in the frail over-80s, Watch small kidney tumours rather than remove them, with a national registry.